Sumanta Kumar Pal, MD, FASCO - Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum

Go online to PeerView.com/DGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovation in renal cell carcinoma (RCC) has brought new opportunities to improve patient outcomes through personalized medicine. With multiple FDA approvals and promising agents being explored in a variety of settings, multitargeted TKIs and immune checkpoint inhibitors have earned their place in cancer care plans either as guideline-recommended therapy or through clinical trial enrollment. In this activity, which was based on a recent live event, a panel of expert oncologists combines a concise overview of essential research on approved and emerging RCC treatments with discussion of real-life patient cases to provide guidance on integrating validated strategies into everyday patient care. Learn how patient-, disease-, and treatment-specific factors affect therapeutic selection and sequencing—including when to consider adjuvant therapy, which patients may benefit from immunotherapy-based combination regimens in the frontline setting, and how to determine which strategies to recommend for patients with relapsed disease. Hear guidance on collaborative approaches to managing adverse events, insights on the use of emerging agents, and updates on clinical trials underway. Upon completion of this activity, participants should be better able to: Evaluate treatment efficacy and safety of approved and emerging therapeutic regimens for patients with RCC; Select personalized therapeutic strategies based on current evidence and patient-, disease-, and treatment-specific factors for patients with RCC; and Integrate strategies to anticipate, mitigate, and manage various adverse events associated with treatments for patients with RCC